New drug cocktail aims to tame stubborn arthritis

NCT ID NCT07491016

Recruiting now Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a combination of two drugs, telitacicept and baricitinib, can help people with difficult-to-treat rheumatoid arthritis. The trial will enroll 30 adults aged 18 to 85 who have not responded to other treatments. Researchers will measure joint swelling and pain, and watch for side effects like liver or kidney problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: telitacicept and baricitinib
What this could lead to: If it works, this could offer a new treatment option for people with rheumatoid arthritis that hasn't improved with standard therapies.
What could go wrong: This is a very small, early-stage study with only 30 participants, so results may not apply to everyone. The combination may cause side effects like liver or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Compliance rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS TELITACICEPT TREATMENT COMPLIANCE

Contacts and locations

Locations

Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.